Akero Therapeutics, Inc. Files SEC Form 144, Report of Proposed Sale of Securities: (Dec. 29, 2023).
In: Drug Week, 2024-01-19, S. 2926
serialPeriodical
Zugriff:
Akero Therapeutics, Inc. has filed a Form 144 with the U.S. Securities and Exchange Commission (SEC) on December 29, 2023. The form indicates the proposed sale of restricted securities or securities held by an affiliate of the company. This filing is required when the amount to be sold exceeds 500 shares or units or has an aggregate sales price over $10,000. Akero Therapeutics, Inc. is a healthcare biotechnology company based in South San Francisco, California. For more information, the SEC filing can be found at the provided link. [Extracted from the article]
Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Akero Therapeutics, Inc. Files SEC Form 144, Report of Proposed Sale of Securities: (Dec. 29, 2023).
|
---|---|
Zeitschrift: | Drug Week, 2024-01-19, S. 2926 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6440 (print) |
Sonstiges: |
|